Gujarat Kidney IPO will open for subscription on December 22, 2025 and close on December 24, 2025. This is a mainboard Book Built Issue through which the company aims to raise approximately ₹250.80 crores. The issue comprises a fresh issue of ₹250.80 crores along with an offer for sale of up to [. ] equity shares, each having a face value of ₹2.
The price band for the Gujarat Kidney IPO has been fixed at ₹108 to ₹114 per share. The IPO is proposed to be listed on both BSE and NSE on December 30, 2025. The basis of allotment is expected to be finalised on December 26, 2025.
Contents
Gujarat Kidney IPO Details
| Particulars | Details |
|---|---|
| IPO Open Date | December 22, 2025 |
| IPO Close Date | December 24, 2025 |
| Face Value | ₹2 per equity share |
| Price Band | ₹108 to ₹114 per share |
| Issue Size | Approx ₹250.80 crores |
| Fresh Issue | Approx ₹250.80 crores |
| Issue Type | Book Built Issue |
| Listing | BSE, NSE |
| Allotment Date | December 26, 2025 |
| Listing Date | December 30, 2025 |
| DRHP Draft Prospectus | View PDF |
| RHP Draft Prospectus | View PDF |
| Anchor Investors List | View PDF |
Gujarat Kidney IPO
Open: 22-24 Dec
Issue Size: ₹250.80 Cr.
Objective: Fund hospital expansions, buy equipment, repay debt and grow operations.
Exchange: BSE NSE
Gujarat Kidney IPO GMP Today
Gujarat Kidney IPO GMP is showing steady strength in the grey market, reflecting positive listing expectations. As per the latest available data, the GMP stands at ₹7, indicating an estimated listing price of around ₹121 against the upper IPO price band of ₹114. This suggests an expected gain of about 6.14% per share.
Over the last seven sessions, GMP movement has remained largely stable, with a brief spike earlier, pointing towards consistent demand rather than speculative volatility. The GMP range has moved between ₹0 and ₹10, which shows improving sentiment as the IPO opening approaches.
Overall, the current trend indicates a decent listing outlook, supported by stable grey market activity and sustained buyer interest.
Gujarat Kidney IPO Day-wise GMP Trend:
| Date | GMP | Estimated Listing Price | Expected Gain |
|---|---|---|---|
| 21-12-2025 | ₹7 (No Change) | ₹121 | 6.14% |
| 20-12-2025 | ₹7 (No Change) | ₹121 | 6.14% |
| 19-12-2025 | ₹7 (Down) | ₹121 | 6.14% |
| 18-12-2025 | ₹10 (Up) | ₹124 | 8.77% |
| 17-12-2025 | ₹0 (No Change) | ₹114 | 0.00% |
| 16-12-2025 | ₹0 (No Change) | ₹114 | 0.00% |
| 15-12-2025 | ₹0 (No Change) | ₹114 | 0.00% |
The table clearly shows that Gujarat Kidney IPO GMP remained flat in the recent sessions after an initial upward move. The rise to ₹10 earlier highlighted strong interest, while the current stable GMP of ₹7 suggests balanced demand and controlled expectations.
Such a trend usually points towards a reasonable listing premium rather than an aggressive spike, which is considered healthier for long-term market confidence.
Disclaimer: GMP is based on grey market news. We do not trade or recommend trading in the grey market or Subject to Sauda (sub2) rates.
Gujarat Kidney IPO Review
Gujarat Kidney IPO comes from a rapidly expanding multispeciality hospital group operating across Gujarat. The company has delivered strong growth in revenue and profitability in FY2025, supported by improved operating margins and low debt levels.
Given the aggressive expansion plans and improving financial metrics, the IPO may be suitable for investors with a long-term investment outlook.
Gujarat Kidney IPO Market Lot Size
| Application Type | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 128 | ₹14,592 |
| Retail Maximum | 13 | 1,664 | ₹1,89,696 |
| S-HNI Minimum | 14 | 1,792 | ₹2,04,288 |
| S-HNI Maximum | 68 | 8,704 | ₹9,92,256 |
| B-HNI Minimum | 69 | 8,832 | ₹10,06,848 |
IPO Reservation Structure
| Investor Category | Allocation |
|---|---|
| QIB (Ex-Anchor) | 75% |
| NII (HNI) | 15% |
| Retail Investors | 10% |
Gujarat Kidney IPO Anchor Investors
| Particulars | Details |
|---|---|
| Anchor Bidding Date | December 19, 2025 |
| Shares Offered | [. ] Shares |
| Anchor Issue Size | [. ] Crores |
| Lock-in (50% – 30 Days) | January 25, 2026 |
| Lock-in (50% – 90 Days) | March 26, 2026 |
- Also Read: EPW India IPO ( 22-24 Dec)
Gujarat Kidney IPO Important Dates
| Event | Date |
|---|---|
| IPO Opens | December 22, 2025 |
| IPO Closes | December 24, 2025 |
| Basis of Allotment | December 26, 2025 |
| Refunds Initiation | December 29, 2025 |
| Shares Credited to Demat | December 29, 2025 |
| IPO Listing | December 30, 2025 |
| Cut-off Time | December 24, 2025 – 5 PM |
Promoters and Shareholding
The promoters of the company are Dr. Pragnesh Yashwantsinh Bharpoda, Dr. Bhartiben Pragnesh Bharpoda, Dr. Yashwantsingh Motisinh Bharpoda, and Anitaben Yashwantsinh Bharpoda.
| Particulars | Shares | Holding |
|---|---|---|
| Pre-Issue | 5,68,43,250 | 99.10% |
| Post-Issue | 7,88,43,250 | 71.45% |
Objects of the Issue
The company plans to utilise the IPO proceeds for strategic expansion and strengthening of its healthcare infrastructure. The funds will be used for acquiring Parekhs Hospital in Ahmedabad, part-payment for Ashwini Medical Centre, and setting up a new hospital in Vadodara.
A portion will also be utilised for purchasing advanced robotic equipment, repaying certain secured borrowings, acquiring additional stake in Harmony Medicare Private Limited at Bharuch, and meeting general corporate requirements.
About the Company
Gujarat Kidney and Super Speciality Limited was incorporated in 2019 and operates a network of multispeciality hospitals across Gujarat. The company offers secondary and tertiary healthcare services across disciplines such as internal medicine, general surgery, orthopaedics, joint replacement, obstetrics and gynaecology, cardiology, diabetology, trauma care, and anaesthesiology.
At present, the company operates seven multispeciality hospitals and four pharmacies located in Vadodara, Godhra, Bharuch, Borsad, and Anand.
Financial Performance
| Financial Year | Revenue | Expenses | PAT | Assets |
|---|---|---|---|---|
| 2023 | 0.00 | 0.01 | 0.01 | 3.87 |
| 2024 | 5.48 | 3.21 | 1.71 | 20.53 |
| 2025 | 40.40 | 27.63 | 9.50 | 55.34 |
| June 2025 | 15.27 | 7.78 | 5.40 | 61.59 |
Valuation and Key Ratios (FY2025)
| KPI | Value |
|---|---|
| ROE | 36.61% |
| ROCE | 37.65% |
| EBITDA Margin | 41.12% |
| PAT Margin | 23.61% |
| Debt-Equity Ratio | 0.15 |
| EPS (Basic) | ₹1.85 |
| NAV | ₹5.04 |
Peer Comparison
| Company | EPS | P/E | RoNW | Income |
|---|---|---|---|---|
| Yatharth Hospital | 14.72 | 55.84 | 8.13% | ₹880.49 Cr |
| GPT Healthcare | 6.08 | 24.51 | 20.14% | ₹407.09 Cr |
| KMC Speciality Hospitals | 1.31 | 52.60 | 13.04% | ₹231.60 Cr |
Company Address
| Particulars | Details |
|---|---|
| Company Name | Gujarat Kidney and Super Speciality Limited |
| Address | Plot No. 1, City Sarve No. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri |
| City & PIN | Vadodara – 390020, Gujarat |
| Phone | +91 265 298 4800 |
| info@gujaratsuperspecialityhospital.com | |
| Website | https://www.gujaratsuperspecialityhospital.com |
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918-6270
Email: gujaratkidney.ipo@in.mpms.mufg.com
Gujarat Kidney IPO FAQs
What is Gujarat Kidney IPO?
Gujarat Kidney IPO is a mainboard public issue through which the company plans to raise ₹250.80 crores. The IPO price band is ₹108 to ₹114 per share.
When will Gujarat Kidney IPO open and close?
The IPO will open on December 22, 2025 and close on December 24, 2025.
What is the lot size for Gujarat Kidney IPO?
Retail investors must apply for a minimum of 128 shares, which amounts to ₹14,592.
What is the allotment and listing date of Gujarat Kidney IPO?
The allotment will be finalised on December 26, 2025, and the shares are expected to list on December 30, 2025.
How is the IPO reserved among investors?
The IPO allocation is 75% for QIBs, 15% for NIIs, and 10% for retail investors.
How can investors apply for Gujarat Kidney IPO?
Investors can apply through ASBA using their bank accounts, UPI via stockbrokers, or by submitting offline IPO application forms.
Expert Comment
Gujarat Kidney IPO reflects strong operational growth, improving margins, and a focused hospital expansion strategy. The low debt level and healthy return ratios provide comfort, though investors should consider the relatively short operating history. Long-term investors seeking exposure to India’s growing healthcare sector may evaluate this IPO carefully.
